SUMMARY OF CHANGES:

INSTRUMENT NOS. 90 to 103 of 2019

Statements of Principles Nos. 90 to 102 of 2019 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 18 October 2019. The day of commencement as specified in each of these Instruments is 18 November 2019. Amendment Statement of Principles No. 103 of 2019 was signed by the Chairperson of the Authority on 23 October 2019. The day of commencement as specified in this Instrument is 22 October 2019.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the Legislation Act 2003 (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from http://www.legislation.gov.au.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the Veterans' Entitlements Act 1986 (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at http://www.rma.gov.au.

For further information contact:

The Registrar
Repatriation Medical Authority
GPO Box 1014
Brisbane  Qld  4001

T  +61 7 3815 9404
F  +61 7 3815 9412
E  info@rma.gov.au

28 October 2019
### SUMMARY OF CHANGES

<table>
<thead>
<tr>
<th>Instr. No.</th>
<th>Title</th>
<th>Date of Commencement</th>
<th>ICD-10-AM Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>REVOCATIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 &amp; 91/2019</td>
<td>microscopic polyangiitis</td>
<td>18/11/2019</td>
<td>M31.7</td>
</tr>
<tr>
<td>92 &amp; 93/2019</td>
<td>malignant neoplasm of the renal pelvis &amp; ureter</td>
<td>18/11/2019</td>
<td>C65, C66</td>
</tr>
<tr>
<td>94 &amp; 95/2019</td>
<td>Ross River virus infection</td>
<td>18/11/2019</td>
<td>B33.1</td>
</tr>
<tr>
<td>96 &amp; 97/2019</td>
<td>acoustic neuroma</td>
<td>18/11/2019</td>
<td>D33.3</td>
</tr>
<tr>
<td>98 &amp; 99/2019</td>
<td>sensorineural hearing loss</td>
<td>18/11/2019</td>
<td>Nil</td>
</tr>
<tr>
<td>100 &amp; 101/2019</td>
<td>subdural haematoma</td>
<td>18/11/2019</td>
<td>S06.5, I62.0</td>
</tr>
<tr>
<td></td>
<td><strong>AMENDMENTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102/2019</td>
<td>cervical spondylosis</td>
<td>18/11/2019</td>
<td>N/A</td>
</tr>
<tr>
<td>103/2019</td>
<td>Ross river virus infection</td>
<td>22/10/2019</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Note:

1. Following its focussed review in respect of carrying loads positioned between the neck and shoulder as a factor in cervical spondylosis, the Authority proposes to amend Statement of Principles No. 66 of 2014. The Authority does not propose to amend Statement of Principles No. 67 of 2014 and a Declaration is expected to appear in the Government Notices Gazette on 29 October 2019 advising of this outcome.

2. Amendment Statement of Principles concerning Ross River virus infection No. 103 of 2019 commenced on 22 October 2019 to rectify a typographical error identified in Statement of Principles concerning Ross River virus infection No. 94 of 2019 following its registration.
| SUMMARY OF CHANGES | 90 & 91/2019 | microscopic polyangiitis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *microscopic polyangiitis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

**For RH & BoP SoPs (Instrument Nos. 90 & 91/2019)**
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'microscopic polyangiitis' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(2) & 9(5) concerning silicosis;
- revising the factors in subsections 9(3) & 9(6) concerning being treated with a drug;
- new definitions of 'MRCA', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; and
- revising the definition of 'relevant service' in Schedule 1 – Dictionary.

The determining of these Instruments finalises the investigation in relation to *microscopic polyangiitis* as advertised in the Government Notices Gazette of 8 May 2018.

| 92 & 93/2019 | malignant neoplasm of the renal pelvis & ureter | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *malignant neoplasm of the renal pelvis and ureter* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

**For RH SoP (Instrument No. 92/2019)**
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'malignant neoplasm of the renal pelvis and ureter' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning smoking;
- revising the factors in subsections 9(3) & 9(4) concerning polycyclic aromatic hydrocarbons;
- revising the factors in subsections 9(5) & 9(6) concerning aromatic amines;
- new factor in subsection 9(7) concerning tetrachloroethylene;
- new factor in subsection 9(8) concerning diesel engine exhaust;
- new factor in subsection 9(9) concerning lead;
- revising the factor in subsection 9(11) concerning working as a painter;
- new factor in subsection 9(12) concerning working as a hairdresser or barber;
- revising the factor in subsection 9(14) concerning hydronephrosis or hydroureter;
- revising the factor in subsection 9(15) concerning chronic renal failure;
- revising the factor in subsection 9(16) concerning aristolochic acid;
- new factor in subsection 9(19) concerning chlornaphazine;
- new factor in subsection 9(20) concerning pioglitazone, or a medication containing pioglitazone;
- new factor in subsection 9(21) concerning diabetes mellitus;
- new factor in subsection 9(22) concerning infection of the renal pelvis or ureter with *Schistosoma haematobium*;
- new factor in subsection 9(23) concerning indwelling ureteric stent or other foreign body in the ureter;
- new factor in subsection 9(24) concerning neurogenic bladder;
- new factor in subsection 9(25) concerning chronic urinary tract infection;
- new definitions of 'being exposed to lead as specified', 'being heavily exposed to diesel engine exhaust', 'chronic renal failure', 'chronic urinary tract infection', 'lead risk work as specified', 'MRCA', 'neurogenic bladder', 'soot', 'specified industrial or manufacturing process 1', 'specified industrial or manufacturing process 2', 'specified list of agents containing high concentrations of polycyclic aromatic hydrocarbons'.
### SUMMARY OF CHANGES

- aromatic amines', 'untreated or mildly treated mineral oils', 'VEA' and 'working as a hairdresser or barber' in Schedule 1 - Dictionary;
- revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'phenacetin', 'relevant service' and 'working as a painter' in Schedule 1 - Dictionary; and
- deleting the definitions of 'an aromatic amine from the specified list' and 'in the specified circumstances'.

#### For BoP SoP (Instrument No. 93/2019)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'malignant neoplasm of the renal pelvis and ureter' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning smoking;
- new factors in subsections 9(3) & 9(4) concerning polycyclic aromatic hydrocarbons;
- new factors in subsections 9(5) & 9(6) concerning aromatic amines;
- new factor in subsection 9(7) concerning tetrachloroethylene;
- new factor in subsection 9(9) concerning working as a painter;
- revising the factor in subsection 9(10) concerning renal stone disease;
- revising the factor in subsection 9(11) concerning hydronephrosis or hydroureret;
- revising the factor in subsection 9(12) concerning chronic renal failure;
- revising the factor in subsection 9(13) concerning aristolochic acid;
- new factor in subsection 9(16) concerning chlornaphazine;
- new definitions of 'chronic renal failure', 'MRCA', 'polycyclic aromatic hydrocarbons', 'soot', 'specified industrial or manufacturing process 1', 'specified industrial or manufacturing process 2', 'specified list of agents containing high concentrations of polycyclic aromatic hydrocarbons', 'specified list of aromatic amines', 'VEA' and 'working as a painter' in Schedule 1 – Dictionary; and
- revising the definitions of 'ingesting aristolochic acid as specified', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'phenacetin' and 'relevant service' in Schedule 1 – Dictionary.

The determining of these Instruments finalises the investigation in relation to *malignant neoplasm of the renal pelvis and ureter* as advertised in the Government Notices Gazette of 6 November 2018.

#### 94 & 95/2019

**Ross River virus infection**

These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *Ross River virus infection* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

#### For RH & BoP SoPs (Instrument Nos. 94 & 95/2019)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'Ross River virus infection' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning being exposed to the Ross River virus;
- revising the factor in subsection 9(2) concerning being in a country or geographic area that has experienced Ross River virus transmission;
- new definitions of 'being exposed to the Ross River virus', 'country or geographic area that has experienced Ross River virus transmission', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
- revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definition of 'an area that is endemic for Ross River virus'.

The determining of these Instruments finalises the investigation in relation to *Ross River virus infection* as advertised in the Government Notices Gazette of 8 May 2018.

#### 96 & 97/2019

**acoustic neuroma**

These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *acoustic neuroma* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH & BoP SoPs (Instrument Nos. 96 & 97/2019)
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'acoustic neuroma' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning ionising radiation;
- new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
- revising the definition of 'relevant service' in Schedule 1 - Dictionary.

The determining of these Instruments finalises the investigation in relation acoustic neuroma as advertised in the Government Notices Gazette of 6 November 2018.

98 & 99/2019 sensorineural hearing loss

These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning sensorineural hearing loss in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH SoP (Instrument No. 98/2019)
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'sensorineural hearing loss' in subsection 7(2);
- new factors in subsections 9(3) & 9(38) concerning explosive blast;
- new factors in subsections 9(4) & 9(39) concerning being struck by lightning;
- revising the factors in subsections 9(5) & 9(40) concerning otitic barotrauma or decompression sickness;
- revising the factors in subsections 9(6) & 9(41) concerning a drug from a class of drugs;
- revising the factors in subsections 9(7) & 9(42) concerning ototopical medication;
- revising the factors in subsections 9(8) & 9(43) concerning taking paracetamol or a nonsteroidal anti-inflammatory drug;
- new factors in subsections 9(9) & 9(44) concerning aspirin;
- revising the factors in subsections 9(10) & 9(45) concerning suppurative bacterial infection;
- revising the factors in subsections 9(11) & 9(46) concerning infection with a virus;
- new factors in subsections 9(12) & 9(47) concerning viral labyrinthitis;
- revising the factors in subsections 9(13) & 9(48) concerning meningitis or encephalitis;
- revising the factors in subsections 9(15) & 9(50) concerning tuberculosis of the meninges, middle ear or inner ear of the affected side;
- revising the factors in subsections 9(17) & 9(52) concerning bone diseases, affecting the petrous temporal bone or middle ear ossicles of the affected side;
- new factors in subsections 9(18) & 9(53) concerning osteoporosis;
- revising the factors in subsections 9(19) & 9(54) concerning autoimmune diseases;
- revising the factors in subsections 9(22) & 9(57) concerning haematological diseases;
- new factors in subsections 9(23) & 9(58) concerning cerebrovascular accident;
- revising the factors in subsections 9(24) & 9(59) concerning lesion interrupting the supply of blood to the cochlea of the affected ear;
- revising the factors in subsections 9(25) & 9(60) concerning blunt trauma, penetrating trauma or surgery to the cochlea or auditory nerve of the affected side;
- new factors in subsections 9(26) & 9(61) concerning moderate to severe traumatic brain injury;
- revising the factors in subsections 9(27) & 9(62) concerning benign or malignant neoplasm involving the affected auditory nerve or cochlea;
- revising the factors in subsections 9(28) & 9(63) concerning therapeutic radiation for cancer;
- revising the factors in subsections 9(29) & 9(64) concerning chemical agents;
- new factors in subsections 9(30) & 9(65) concerning cobalt;
- revising the factors in subsections 9(31) & 9(66) concerning smoking;
- new factors in subsections 9(32) & 9(67) concerning second-hand smoke;
- new factors in subsections 9(34) & 9(69) concerning being obese;
- new factors in subsections 9(35) & 9(70) concerning hypertension;
SUMMARY OF CHANGES

- deleting factors concerning diphtheria, Meniere's disease and being vaccinated with the measles-mumps vaccine;
- new definitions of 'being exposed to second-hand smoke', being obese', 'BMI', 'MRCA', 'ototopical medication as specified', 'specified list of autoimmune diseases', 'specified list of bacterial infections', 'specified list of bone diseases', 'specified list of chemical agents', 'specified list of drugs', 'specified list of haematological diseases' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'dB(A)', 'dB(C)', 'hyperviscosity syndrome', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'relevant service' and 'specified list of viruses' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a course of therapeutic radiation', 'a drug or a drug from a class of drugs from the specified list', 'a specified autoimmune disorder', 'a specified ototopical medication', 'a specified organic solvent', 'alcohol', 'antineoplastic agents as specified', 'meningitis' and 'neurosyphilis'.

For BoP SoP (Instrument No. 99/2019)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'sensorineural hearing loss' in subsection 7(2);
- new factors in subsections 9(3) & 9(31) concerning explosive blast;
- new factors in subsections 9(4) & 9(32) concerning being struck by lightning;
- revising the factors in subsections 9(5) & 9(33) concerning otitic barotrauma or decompression sickness;
- revising the factors in subsections 9(6) & 9(34) concerning a drug from a class of drugs;
- revising the factors in subsections 9(7) & 9(35) concerning ototopical medication;
- revising the factors in subsections 9(8) & 9(36) concerning taking paracetamol or a nonsteroidal anti-inflammatory drug;
- new factors in subsections 9(9) & 9(37) concerning aspirin;
- revising the factors in subsections 9(10) & 9(38) concerning suppurative bacterial infection;
- revising the factors in subsections 9(11) & 9(39) concerning infection with a virus;
- new factors in subsections 9(12) & 9(40) concerning viral labyrinthitis;
- revising the factors in subsections 9(13) & 9(41) concerning meningitis or encephalitis;
- revising the factors in subsections 9(15) & 9(43) concerning tuberculosis of the meninges, middle ear or inner ear of the affected side;
- revising the factors in subsections 9(17) & 9(45) concerning Paget's disease of bone, affecting the petrous temporal bone or middle ear ossicles of the affected side;
- revising the factors in subsections 9(18) & 9(46) concerning autoimmune diseases;
- revising the factors in subsections 9(21) & 9(49) concerning haematological diseases;
- new factors in subsections 9(22) & 9(50) concerning cerebrovascular accident;
- revising the factors in subsections 9(23) & 9(51) concerning lesion interrupting the supply of blood to the cochlea of the affected ear;
- revising the factors in subsections 9(24) & 9(52) concerning blunt trauma, penetrating trauma or surgery to the cochlea or auditory nerve of the affected side;
- revising the factors in subsections 9(25) & 9(53) concerning benign or malignant neoplasm involving the affected auditory nerve or cochlea;
- revising the factors in subsections 9(26) & 9(54) concerning therapeutic radiation for cancer;
- revising the factors in subsections 9(27) & 9(55) concerning chemical agents;
- revising the factors in subsections 9(28) & 9(56) concerning smoking;
- deleting factors concerning Meniere's disease and being vaccinated with the measles-mumps vaccine;
- new definitions of 'hyperviscosity syndrome', 'MRCA', 'ototopical medication as specified', 'specified list of autoimmune diseases', 'specified list of bacterial infections', 'specified list of chemical agents', 'specified list of drugs', 'specified list of haematological diseases' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'dB(A)', 'dB(C)', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'relevant service' and 'specified list of viruses' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a course of therapeutic radiation', 'a drug or a drug from a class of drugs from the specified list', 'a specified autoimmune disorder', 'a specified ototopical medication', 'a specified organic solvent', 'antineoplastic agents as specified', 'meningitis' and 'neurosyphilis'.

Page 6 of 8
On 7 June 2019, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factors relating to diphtheria, Meniere's disease and being vaccinated with the measles-mumps vaccine from the reasonable hypothesis and balance of probabilities Statements of Principles. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor typographical changes were made to the proposed Instruments following this consultation process.

The determining of these Instruments finalises the investigation in relation to sensorineural hearing loss as advertised in the Government Notices Gazette of 8 May 2018.

### 100 & 101/2019

| subdural haematoma | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning subdural haematoma in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

**For RH SoP (Instrument No. 100/2019)**

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'subdural haematoma' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1)(a) concerning head trauma, for intracranial subdural haematoma only;
- new factor in subsection 9(1)(b) concerning intracranial neurosurgery or penetrating cranial trauma, for intracranial subdural haematoma only;
- revising the factor in subsection 9(1)(c) concerning active epilepsy, for intracranial subdural haematoma only;
- revising the factor in subsection 9(1)(d) concerning epileptic seizure, for intracranial subdural haematoma only;
- revising the factor in subsection 9(1)(f) concerning alcohol use disorder, for intracranial subdural haematoma only;
- revising the factor in subsection 9(2) concerning a cerebrospinal procedure;
- revising the factor in subsection 9(3) concerning trauma to the spinal region, for spinal subdural haematoma only;
- revising the factor in subsection 9(5) concerning aspirin;
- revising the factor in subsection 9(6) concerning an acquired disorder resulting in impaired haemostasis;
- revising the factor in subsection 9(7) concerning haemodialysis;
- new factor in subsection 9(8) concerning a cerebrospinal fluid shunt;
- new factor in subsection 9(9) concerning diabetes mellitus;
- deleting clinical onset factors concerning Paget's disease of bone, ankylosing spondylitis and sudden change in intracranial pressure or spinal intravenous pressure and clinical worsening factors relating to antithrombotic therapy, aspirin, an acquired haematological disorder and haemodialysis;
- new definitions of 'active epilepsy', 'cerebrospinal procedure', 'head trauma', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'relevant service', 'specified form of dementia' and 'trauma to the spinal region' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a specified activity', 'an acquired haematological disorder from the specified list' and 'head injury'.

**For BoP SoP (Instrument No. 101/2019)**

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'subdural haematoma' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1)(a) concerning head trauma, for intracranial subdural haematoma only; |
<table>
<thead>
<tr>
<th>Number</th>
<th>Condition</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>102/2019</td>
<td>cervical spondylosis</td>
<td>New factors concerning carrying a large bulky load positioned between the neck and shoulder in paragraphs 6(ia) &amp; 6(va).</td>
</tr>
<tr>
<td>103/2019</td>
<td>Ross River virus infection</td>
<td>Replacing the commencement date in section 2.</td>
</tr>
</tbody>
</table>